Ladenburg Thalmann

Ladenburg Thalmann lowered its rating on Xylem (NYSE: XYL) from Buy to Neutral and reduced its price target from $30 to $27. Ladenburg Thalmann commented, "Continue to believe XYL is among the most attractive stocks in our coverage universe from a long term perspective, offering investors...

Following the market opening Monday morning, the Dow was down about 0.18 percent, roughly 24.75 points. The NASDAQ fell about 0.70 percent, or 22.28 points, while the S&P traded down 0.29 percent, decreasing 4.26 points. Shares of Rock-Tenn (NYSE: RKT) continued to rise midway through Monday,...

Ladenburg Thalmann reduced its rating on Questcor Pharmaceuticals (NASDAQ: QCOR) from Buy to Neutral and removed its prior price target of $45 per share. Ladenburg Thalmann said, "In our view the US government investigation coupled with recent potential reimbursement headwinds create great...

Ladenburg Thalman upgraded Aegion Corporaiton (NASDAQ: AEGN) from Neutral to Buy and increased its price target from $17 to $23. Ladenburg Thalman wrote, “Though not perfect, 2Q12 results suggest the plan management laid out for restoring earnings growth following a difficult 2011 in which...

Ten equity research reports had new Buy ratings from analysts this morning. Below are the stocks that moved the most on the new ratings by the time the news was were reported on by Benzinga Professional. Ladenburg Thalmann on Layne Christensen Ladenburg Thalmann initiated Layne Christensen (...

Ladenburg Thalmann initiates its coverage on Layne Christensen (NASDAQ: LAYN) with a Buy rating and a price target of $25. Ladenburg Thalmann says, "We recognize our BUY rating is a somewhat contrarian call on this stock. Layne is a quintessential rebuilding story, and has all the...

Ladenburg Thalmann has published a research report on GSV Capital (NASDAQ: GSVC) and has lowered the price target from $20.25 to $17.75 as the company has opportunities for exposure in private, emerging growth companies. In the report, Ladenburg Thalmann writes, "According to recent data from...

Ladenburg Thalmann has published a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and has upgraded the company from Neutral to Buy based on valuation. In the report, Ladenburg Thalmann writes, "In essence, despite our view that Feraheme does not represent a great business for AMAG, we...

According to a research report this morning, Ladenburg Thalmann reduces its PT on Bioanalytical Systems (NASDAQ: BASI) from $2.75 to $2.25 following disappointing Q2-2012. Ladenburg Thalmann stated, “The Company announced losing $1.86MM and $0.27 per share on revenue of $6.97MM as compared with...

According to a research report published this morning, Ladenburg Thalmann has increased Prospect Capital's (NASDAQ: PSEC) PT from $11 to $11.50. In the report, Ladenburg Thalmann commented, "During 3Q12 PSEC closed on $171 million of new and follow-on portfolio investments versus $155 million in...

According to a research report published this morning, Ladenburg Thalmann has lowered Full Circle Capital's (NASDAQ: FULL) PT from $8 to $7.50. Ladenburg Thalmann commented in the report, "FULL held its earnings call on May 11, 2012 and reported 3Q12 NOI per share of $0.18 which missed our $0.21...

Ladenburg Thalmann reduces its price target from $38 to $37 on Buy-rated Chesapeake Midstream Partners (NYSE: CHKM) as the firm misses consensus estimates on Earnings Per Unit in Q1. Ladenburg Thalmann notes, "1Q12 Earnings Per Unit (EPU) Below Consensus But In-Line With Our Expectations. For...

Listed below are Benzinga's Top Upgrades: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals (NASDAQ: KERX) to Buy: Ladenburg Thalmann said, "The importance of the Zerenex program has substantially increased following yesterday's announcement of the perifosine data. Zerenex's Phase III program...

Listed below are today's Top Downgrades at Benzinga: ISI Group Downgrades Staples (NASDAQ: SPLS) to Sell: ISI Group commented, "We are downgrading Staples to Sell from Hold, as the stock has bounced 8% ytd, yet secular fundamentals have not improved, European headwinds remain, and our surveys...

According to a research report published this morning, Ladenburg Thalmann has upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Buy, and established a $3 PT. In the report, Ladenburg Thalmann said, "The importance of the Zerenex program has substantially increased following...